Quick Answer: On November 9, 2026, the FDA told the makers of all GLP-1 receptor agonists to add a warning about a potential increased risk of NAION (non-arteritic anterior ischemic optic neuropathy), a rare condition that causes sudden, painless vision loss in one eye (FDA Drug Safety Communication). The order covers Ozempic, Wegovy and Rybelsus (semaglutide), Mounjaro and Zepbound (tirzepatide), Trulicity, Victoza, Saxenda, the insulin combinations Xultophy and Soliqua, generic exenatide and the 2026 oral drug Foundayo. In the FDA’s pooled trial analysis, NAION occurred at 6.4 vs 3.8 cases per 100,000 person-years on GLP-1s versus comparators: a real signal, but a small absolute risk based on just 15 cases. Don’t stop your medicine on your own; call a clinician right away for any sudden vision change in one eye.
Which GLP-1 Drugs Are Affected
The FDA applied the warning to the whole class instead of singling out one molecule. It says NAION cases have been reported for every currently marketed GLP-1 product (FDA). The table follows the FDA’s list; the “main labeled use” column is simplified, and several of these drugs carry extra approved uses (heart, kidney, sleep apnea or liver indications).
| Brand | Active ingredient | Main labeled use | NAION warning required? |
|---|---|---|---|
| Exenatide (generic; Byetta withdrawn) | exenatide | Type 2 diabetes | Yes |
| Victoza | liraglutide | Type 2 diabetes | Yes |
| Saxenda | liraglutide | Weight management | Yes |
| Xultophy | liraglutide + insulin degludec | Type 2 diabetes | Yes |
| Trulicity | dulaglutide | Type 2 diabetes | Yes |
| Soliqua | lixisenatide + insulin glargine | Type 2 diabetes | Yes |
| Ozempic | semaglutide (weekly injection) | Type 2 diabetes | Yes |
| Rybelsus | semaglutide (daily tablet) | Type 2 diabetes | Yes |
| Wegovy | semaglutide | Weight management | Yes |
| Mounjaro | tirzepatide (GIP + GLP-1) | Type 2 diabetes | Yes |
| Zepbound | tirzepatide (GIP + GLP-1) | Weight management | Yes |
| Foundayo | orforglipron (oral, approved 2026) | See label | Yes |
Tirzepatide acts on both the GIP and GLP-1 receptors, but the FDA still includes it in the class for this warning. Compounded semaglutide or tirzepatide is not FDA-approved and has no FDA label to update, but it contains the same active ingredients, so the same eye symptoms deserve the same urgent attention.
What Exactly Changed on the Label
- Where: the Warnings and Precautions section of each label. This is not a new boxed warning. The existing boxed warning about thyroid C-cell tumors seen in rodents is unchanged.
- What it says: a potential increased risk of NAION, with permanent vision loss possible.
- Advice to prescribers: tell patients to report sudden, painless vision loss, visual-field gaps or other one-eye visual disturbances at once; refer suspected cases promptly to an ophthalmologist; and consider stopping the GLP-1 if NAION develops, unless the benefits clearly outweigh the risk (FDA MedWatch alert).
- Timing: the FDA is requiring application holders to submit the change. Printed inserts and DailyMed listings update as each company’s revision is processed, so the package insert in your box may not show the new text yet.
How Big Is the Risk? The FDA’s Numbers
The FDA looked at four kinds of evidence. Here is what each one showed, in the agency’s words and figures (FDA):
| Evidence | What it found | Caveat |
|---|---|---|
| Meta-analysis of 126 randomized trials (134,253 patients; 288,879 person-years) | 6.4 NAION cases per 100,000 person-years on GLP-1s vs 3.8 on placebo or non-GLP-1 glucose-lowering drugs | Only 15 probable cases in total (10 on GLP-1s, 5 on placebo, 0 on other diabetes drugs) |
| FDA Sentinel real-world cohort (adults with type 2 diabetes starting a drug, 2019–2024) | Incidence 30–32 per 100,000 person-years on GLP-1s, 31 on SGLT-2 inhibitors, 26 on DPP-4 inhibitors | No significant difference vs SGLT-2 inhibitors (HR 1.19, 95% CI 0.91–1.54); higher risk vs DPP-4 inhibitors (HR 1.43, 95% CI 1.02–2.01) |
| Published observational studies | Rigorous studies consistently found higher NAION risk in people with type 2 diabetes starting GLP-1s vs DPP-4 or SGLT-2 inhibitors | Observational data can’t fully separate the drug from the conditions it treats |
| Animal data | No mechanism identified | The “how” is still unknown |
Put into plain numbers, the trial gap of 2.6 cases per 100,000 person-years works out to roughly one extra case for every 38,000 or so years of patient treatment. For context, the FDA cites a background NAION rate of 2.3 to 10.2 cases per 100,000 people per year in adults over 50. The real-world rates in people with diabetes (26–32 per 100,000 person-years) were several times higher than in the trials, which fits the fact that diabetes itself is a NAION risk factor.
FDA vs Europe: How the Two Conclusions Compare
Europe moved first. In June 2025, the European Medicines Agency’s safety committee (PRAC) concluded that NAION is a “very rare” side effect of semaglutide (Ozempic, Rybelsus, Wegovy), affecting up to 1 in 10,000 people taking it, and said treatment should be stopped if NAION is confirmed (EMA). The World Health Organization relayed that alert later in June 2025 (WHO).
| FDA (Nov 9, 2026) | EMA PRAC (June 6, 2025) | |
|---|---|---|
| Drugs covered | Every GLP-1 receptor agonist, including tirzepatide and orforglipron | Semaglutide medicines only |
| Wording | “Potential increased risk” | “Very rare” side effect (up to 1 in 10,000) |
| Size of effect cited | 6.4 vs 3.8 per 100,000 person-years in trials | About a two-fold risk in type 2 diabetes studies, roughly 1 extra case per 10,000 person-years |
| If NAION occurs | Consider stopping unless benefits clearly outweigh the risk | Stop semaglutide |
The two agencies used different data sets, so their numbers aren’t directly comparable. Both land on the same practical message: the risk is rare, and sudden vision loss on one of these drugs needs urgent eye care.
Where the Concern Started
The FDA traces its review to a July 2024 study in JAMA Ophthalmology from Massachusetts Eye and Ear (Hathaway et al., 2024). Among patients seen by neuro-ophthalmologists, people with type 2 diabetes prescribed semaglutide had a higher NAION risk than those on other diabetes drugs (hazard ratio 4.28; 36-month cumulative incidence 8.9% vs 1.8%), with a similar signal in people with overweight or obesity. Because the patients came from a single specialty referral center, the absolute numbers are much higher than in the general population, and the FDA noted “several limitations” before running its own analyses.
Symptoms to Act On
- Sudden, painless loss of vision in one eye, often noticed when you wake up
- Blurry or missing parts of your vision (a blind spot, a dark area at the top or bottom, tunnel vision)
- Colors looking faded or distorted
- Reduced central sharpness, such as hazy or blurry spots
The FDA advises contacting a health care professional right away if any of these happen (FDA). Ask for a same-day eye exam. Some strokes and other emergencies also cause sudden vision loss, so don’t wait to see whether it improves. NAION itself is painless; a painful red eye or vision loss with headache, jaw pain or scalp tenderness points to other urgent conditions.
Who Should Pay Closest Attention
The FDA lists possible NAION risk factors as smoking, diabetes, high blood pressure, sleep apnea, anemia and kidney disease, and says a prior NAION in one eye raises the risk in the other (FDA). Many people prescribed GLP-1 drugs have one or more of these. If you have had NAION before, or have a known “crowded” optic disc, tell your prescriber before you start or continue a GLP-1.
Does This Change Which GLP-1 to Choose?
Not on current evidence. The FDA applied an identical warning across the class and did not rank products by NAION risk. There are no head-to-head data showing that switching from semaglutide to tirzepatide, or from an injection to Foundayo, lowers the risk. Choice between these drugs still turns mainly on indication, weight-loss and glucose results, side effects, dosing and coverage, as covered in our semaglutide vs tirzepatide comparison. For type 2 diabetes, the background comparison with metformin is in Metformin vs Ozempic.
The Sentinel result is a useful nuance for diabetes care: NAION rates on GLP-1s were statistically similar to those on SGLT-2 inhibitors and higher than on DPP-4 inhibitors. Because GLP-1s and SGLT-2 inhibitors also carry heart and kidney benefits, any switch is a trade-off to weigh with your prescriber, not a reflex.
What to Do Now
- No symptoms: the FDA is not advising anyone to stop. Keep taking your medicine as prescribed and raise the warning at your next visit if you have NAION risk factors.
- Sudden vision change in one eye: call your clinician or go to urgent eye care the same day and say you take a GLP-1 drug.
- Diagnosed with NAION: talk with your clinician about whether to continue. The FDA says to consider stopping unless the benefits clearly outweigh the risk.
- Report it: side effects can be reported to the FDA’s MedWatch program or by calling 1-800-332-1088.
Frequently Asked Questions
Which GLP-1 drugs get the new NAION warning?
All of them. The FDA’s November 9, 2026 Drug Safety Communication applies to every GLP-1 receptor agonist: exenatide, Victoza and Saxenda (liraglutide), Xultophy, Trulicity (dulaglutide), Soliqua, Ozempic, Rybelsus and Wegovy (semaglutide), Mounjaro and Zepbound (tirzepatide) and Foundayo (orforglipron).
What is NAION?
Non-arteritic anterior ischemic optic neuropathy is damage to the front of the optic nerve from reduced blood flow. It typically causes sudden, painless vision loss in one eye, often noticed on waking, and the loss can be permanent. There is no proven treatment.
How big is the risk?
Small in absolute terms. In the FDA’s analysis of 126 randomized trials, NAION occurred at 6.4 cases per 100,000 person-years on GLP-1 drugs versus 3.8 per 100,000 on placebo or other glucose-lowering drugs. That analysis rested on only 15 probable cases, so the estimate is imprecise.
Is Mounjaro or Zepbound safer for the eyes than Ozempic or Wegovy?
The FDA did not rank the drugs. It applied the same warning to the whole class and says NAION cases have been reported with every marketed GLP-1 product. There is no head-to-head evidence that switching from semaglutide to tirzepatide or another GLP-1 lowers NAION risk.
Should I stop my GLP-1 medicine because of this warning?
Not on your own. The FDA is not telling patients without symptoms to stop. It advises contacting a health care professional right away for sudden vision changes, and, if NAION has occurred, discussing with your clinician whether to continue.
What symptoms should make me call a doctor right away?
Sudden, painless loss of vision in one eye, blurry or missing areas of vision such as blind spots or tunnel vision, colors that look washed out, or reduced central sharpness. Ask for prompt referral to an ophthalmologist.
Who is at higher risk of NAION?
The FDA lists smoking, diabetes, high blood pressure, sleep apnea, anemia and kidney disease as possible risk factors, and notes that people who have had NAION in one eye are at higher risk in the other eye. Many of these overlap with the reasons people take GLP-1 drugs.
Sources
- FDA Drug Safety Communication (Nov 9, 2026): FDA requires safety labeling changes for GLP-1 RAs due to potential increased risk of rare but serious eye condition
- FDA MedWatch Alert (Nov 9, 2026): GLP-1 RA safety labeling changes
- European Medicines Agency (June 6, 2025): PRAC concludes NAION is a very rare side effect of semaglutide medicines
- World Health Organization (June 27, 2025): Semaglutide medicines and risk of NAION
- Hathaway JT et al. Risk of NAION in patients prescribed semaglutide. JAMA Ophthalmol. 2024;142(8):732-739
- Pharmacy Times (Nov 2026): FDA requires class-wide GLP-1 RA labeling changes for potential NAION risk
- NBC News (Nov 9, 2026): FDA orders new warning on GLP-1s over rare eye condition
- FDA: MedWatch Safety Information and Adverse Event Reporting Program
Medical disclaimer: This article is for educational purposes and does not replace medical advice. Consult a licensed healthcare provider before starting any supplement, medication, or treatment — particularly if you are pregnant, breastfeeding, taking other medications, or have a diagnosed medical condition. Do not stop a prescribed GLP-1 medicine without talking to your prescriber, and seek urgent care for sudden vision loss.